Opendata, web and dolomites



Total Cost €


EC-Contrib. €






Project "EPIRIN" data sheet

The following table provides information about the project.


Organization address
postcode: 34450

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Turkey [TR]
 Project website
 Total cost 157˙845 €
 EC max contribution 157˙845 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2014
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2015
 Duration (year-month-day) from 2015-05-01   to  2017-04-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KOC UNIVERSITY TR (ISTANBUL) coordinator 157˙845.00


 Project objective

Non-alcoholic fatty liver disease (NAFLD) is a rapidly growing clinical problem, affecting a third of the European population. The transition of hepatic fat accumulation to inflammation is the key event taking place in the progression of NAFLD. This is controlled by a number of inflammatory and immune pathways including the activity of Natural Killer (NK) and Natural Killer T (NKT) cells. Progression from hepatic lipid deposition to inflammation and cirrhosis also follows a substantially variable course. It has been estimated that less than 10% of patients develop end-stage liver disease. Individual variability for disease progression is partly controlled by environmental factors and genetic background. However, it is not known how immune and inflammatory pathways are orchestrated by epigenetic mechanisms. The project hypothesises that “NK and NKT cells are programmed into inflammatory state by epigenetic modifications in progression from fatty liver to inflammation”. In this project, histone modifications and DNA methylation will be studied by genome-wide and loci-specific approaches in NK and NKT cells purified from animal models of NAFLD and a prospectively-designed human NAFLD cohort. Reversibility of these modifications will be investigated following the regression of liver disease in animal models and after the implementation of lifestyle changes in humans. Lastly, the therapeutic potential of targeting histone modifying enzymes by short hairpin RNA and small molecule inhibitors in NK and NKT cells for modulating inflammatory response will be investigated. The project will be the first comprehensive study investigating cross-talking epigenetic mechanisms in NK and NKT cells in NAFLD.


year authors and title journal last update
List of publications.
2017 Timothy Hardy, Mujdat Zeybel, Christopher P Day, Christian Dipper, Steven Masson, Stuart McPherson, Elsbeth Henderson, Dina Tiniakos, Steve White, Jeremy French, Derek A Mann, Quentin M Anstee, Jelena Mann
Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease
published pages: 1321-1328, ISSN: 0017-5749, DOI: 10.1136/gutjnl-2016-311526
Gut 66/7 2019-07-24
2016 M?jdat Zeybel, Sezgin Vatansever, Timothy Hardy, Ay?eg?l Akder Sar?, Fulya Cakala?ao?lu, Arzu Avc?, Gemma Louise Zeybel, Ser?in Karah?seyino?lu, Matthew Bashton, John C. Mathers, Belk?s ?nsal, Jelena Mann
DNA methylation profiling identifies novel markers of progression in hepatitis B-related chronic liver disease
published pages: , ISSN: 1868-7075, DOI: 10.1186/s13148-016-0218-1
Clinical Epigenetics 8/1 2019-07-24
2017 Gemma L. Zeybel, Jeffrey P. Pearson, Amaran Krishnan, Stephen J. Bourke, Simon Doe, Alan Anderson, Shoaib Faruqi, Alyn H. Morice, Rhys Jones, Melissa McDonnell, Mujdat Zeybel, Peter W. Dettmar, Malcolm Brodlie, Chris Ward
Ivacaftor and symptoms of extra-oesophageal reflux in patients with cystic fibrosis and G551D mutation
published pages: 124-131, ISSN: 1569-1993, DOI: 10.1016/j.jcf.2016.07.004
Journal of Cystic Fibrosis 16/1 2019-07-24
2017 Müjdat Zeybel, Saimir Luli, Laura Sabater, Timothy Hardy, Fiona Oakley, Jack Leslie, Agata Page, Eva Moran Salvador, Victoria Sharkey, Hidekazu Tsukamoto, David C.K. Chu, Uma Sharan Singh, Mirco Ponzoni, Patrizia Perri, Daniela Di Paolo, Edgar J. Mendivil, Jelena Mann, Derek A. Mann
A Proof-of-Concept for Epigenetic Therapy of Tissue Fibrosis: Inhibition of Liver Fibrosis Progression by 3-Deazaneplanocin A
published pages: 218-231, ISSN: 1525-0016, DOI: 10.1016/j.ymthe.2016.10.004
Molecular Therapy 25/1 2019-07-24

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EPIRIN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EPIRIN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

MIGPSC (2018)

Shaping the European Migration Policy: the role of the security industry

Read More  

NPsVLCD (2019)

Natural Product-Inspired Therapies for Leishmaniasis and Chagas Disease

Read More  

NaWaTL (2020)

Narrative, Writing, and the Teotihuacan Language: Exploring Language History Through Phylogenetics, Epigraphy and Iconography

Read More